Study guide
11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy
Key Takeaways Explain This Topic AI
Tumor Lysis Syndrome (TLS) is characterized by rapid intracellular release of potassium, phosphorus, and nucleic acids (uric acid) following effective antineoplastic therapy in high-turnover hematologic malignancies.
Cairo-Bishop criteria define laboratory TLS (≥2 abnormal values: Uric acid ≥8.0 mg/dL, Potassium ≥6.0 mEq/L, Phosphorus ≥4.5 mg/dL, Calcium ≤7.0 mg/dL) and clinical TLS (lab TLS plus renal failure, cardiac arrhythmia, or seizures).
Rasburicase (recombinant urate oxidase) rapidly degrades existing uric acid to soluble allantoin and is indicated for high-risk TLS, but is strictly contraindicated in G6PD deficiency due to life-threatening hemolysis and methemoglobinemia.
Hypercalcemia of Malignancy (HCM) is primarily mediated by tumor secretion of PTHrP (80%) or osteolytic bone destruction (20%), presenting with acute polyuria, dehydration, constipation, confusion, and QTc shortening.
First-line HCM management requires aggressive IV normal saline hydration (200-500 mL/hr) followed by IV bisphosphonates (Zoledronic acid 4 mg) or Denosumab (120 mg SC, preferred in severe renal impairment).
Last updated: August 2026
Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy
Metabolic oncologic emergencies result from severe electrolyte, mineral, and metabolic derangements triggered by rapid malignant cell turnover or systemic tumor-derived humoral factors. Tumor Lysis Syndrome (TLS) and Hypercalcemia of Malignancy (HCM) represent the two most common metabolic emergencies encountered by Advanced Practice Registered Nurses (APRNs). Prompt identification and aggressive intervention are crucial to prevent acute kidney injury, lethal cardiac dysrhythmias, and mortality.
1. Pathophysiology of Tumor Lysis Syndrome
TLS occurs when massive quantities of neoplastic cells lyse rapidly, overwhelming physiological clearance mechanisms and releasing intracellular contents—potassium, phosphorus, and nucleic acids—into the systemic circulation.
Metabolic Cascades
Hyperuricemia : Purine nucleic acids released from lysed tumor cells are metabolized by xanthine oxidase into uric acid. Uric acid is poorly soluble in acidic tubular fluid, leading to acute uric acid nephropathy, renal tubular precipitation, and obstructive acute kidney injury (AKI).
Hyperkalemia : Rapid release of intracellular potassium ( K + K^+ K + ) into extracellular fluid. Represents the most immediately lethal component of TLS, precipitating severe cardiac conduction abnormalities and fatal ventricular dysrhythmias.
Hyperphosphatemia & Hypocalcemia : Intracellular phosphate concentrations in malignant lymphoblasts are up to 4-fold higher than normal mature lymphocytes. Rapid phosphate release causes hyperphosphatemia, which precipitates with calcium to form calcium-phosphate crystals in renal tubules ( C a × P product > 60 mg 2 / dL 2 Ca \times P \text{ product } > 60\text{ mg}^2/\text{dL}^2 C a × P product > 60 mg 2 / dL 2 ). Subsequent binding of ionized calcium leads to acute secondary hypocalcemia (tetany, seizures, QTc prolongation).
High-Risk Malignancies
Burkitt lymphoma, T-cell Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) with high white blood cell count ( > 50 , 000 / μ L >50,000/\mu\text{L} > 50 , 000/ μ L ), bulky High-Grade Non-Hodgkin Lymphoma, and rapidly proliferating solid tumors treated with potent targeted therapies (e.g., venetoclax in CLL).
2. Cairo-Bishop Diagnostic Criteria for TLS
The Cairo-Bishop Definition establishes standardized classification for Laboratory TLS (LTLS) and Clinical TLS (CTLS).
Cairo-Bishop Classification Matrix
Classification Diagnostic Criteria Timing / Parameters
Laboratory TLS (LTLS) ≥ 2 \ge 2 ≥ 2 electrolyte abnormalities present within 3 days before or 7 days after therapy initiation. • Uric Acid : ≥ 8.0 mg/dL \ge 8.0\text{ mg/dL} ≥ 8.0 mg/dL (or 25% increase from baseline); • Potassium : ≥ 6.0 mEq/L \ge 6.0\text{ mEq/L} ≥ 6.0 mEq/L (or 25% increase); • Phosphorus : ≥ 4.5 mg/dL \ge 4.5\text{ mg/dL} ≥ 4.5 mg/dL (or 25% increase); • Calcium : ≤ 7.0 mg/dL \le 7.0\text{ mg/dL} ≤ 7.0 mg/dL (or 25% decrease)
Clinical TLS (CTLS) Laboratory TLS PLUS ≥ 1 \ge 1 ≥ 1 clinical toxicity directly attributable to metabolic derangements. • Acute Kidney Injury : Serum creatinine ≥ 1.5 × \ge 1.5 \times ≥ 1.5 × upper limit of normal; • Cardiac Arrhythmias / Sudden Death ; • Seizures
3. TLS Prevention & Management Protocols TLS Risk Assessment (Malignancy Type, Tumor Bulk, Baseline Renal Function)
│
├─► High Risk (Burkitt, ALL, AML WBC >50k, Bulk >10cm) ──► IV NS 2.5-3.0 L/m²/day + Rasburicase (0.15-0.2 mg/kg)
- ├─► Intermediate Risk (DLBCL, Moderate Bulk) ──────────► IV NS 2.5-3.0 L/m²/day + Allopurinol (300 mg PO QD)
- └─► Low Risk ──────────────────────────────────────────► Oral Hydration + Close Monitoring
- Aggressive Intravenous Hydration
Administer IV 0.9% Normal Saline at 2.5 – 3.0 L/m 2 / day 2.5–3.0\text{ L/m}^2/\text{day} 2.5–3.0 L/m 2 / day ( 200 – 300 mL/hr 200–300\text{ mL/hr} 200–300 mL/hr ) to expand intravascular volume, enhance renal perfusion, and promote continuous flushing of uric acid and calcium-phosphate crystals.
Target urine output: ≥ 100 mL/m 2 / hr \ge 100\text{ mL/m}^2/\text{hr} ≥ 100 mL/m 2 / hr ( ≥ 2 mL/kg/hr \ge 2\text{ mL/kg/hr} ≥ 2 mL/kg/hr ). Note : Exogenous urinary alkalinization (sodium bicarbonate) is no longer recommended due to increased calcium-phosphate crystallization.
Anti-Hyperuricemic Pharmacotherapy
Allopurinol (Xanthine Oxidase Inhibitor):
Dose : 300 mg PO daily (adjust for renal impairment).
Mechanism : Blocks conversion of hypoxanthine to xanthine and uric acid. Prevents new uric acid formation but does not clear pre-existing serum uric acid. Used for low-to-intermediate risk TLS prophylaxis.
Rasburicase (Recombinant Urate Oxidase):
Dose : 0.15 – 0.20 mg/kg 0.15–0.20\text{ mg/kg} 0.15–0.20 mg/kg IV single dose (or fixed 3–6 mg dose).
Mechanism : Enzymatically cleaves existing insoluble uric acid into allantoin , a highly soluble inactive metabolite excreted readily by kidneys. Rapidly lowers uric acid within 4 hours.
Indication : High-risk TLS or pre-existing hyperuricemia.
CRITICAL CONTRAINDICATION : Strictly contraindicated in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency . Hydrogen peroxide generated during urate oxidation causes severe methemoglobinemia and fatal hemolytic anemia.
Lab Handling : Blood samples for post-rasburicase uric acid testing must be drawn in pre-chilled heparin tubes and immediately immersed in an ice bath to prevent ex vivo degradation of uric acid by rasburicase at room temperature.
Electrolyte Derangement Protocols
Hyperkalemia : IV Calcium Gluconate (1 g IV over 5 min) for cardiac membrane stabilization, followed by Regular Insulin (10 units IV) + 50% Dextrose (50 mL IV), inhaled Albuterol, loop diuretics, and sodium zirconium cyclosilicate. Initiate emergent hemodialysis if refractory.
Hyperphosphatemia : Administer oral phosphate binders (sevelamer hydrochloride); restrict dietary phosphate.
Hypocalcemia : Treat only if clinically symptomatic (tetany, QTc prolongation) using low-dose IV calcium gluconate to avoid accelerating tissue calcium-phosphate precipitation.
4. Pathophysiology of Hypercalcemia of Malignancy (HCM)
HCM occurs in up to 30% of cancer patients. It is categorized into four distinct pathophysiological mechanisms:
Humoral Hypercalcemia of Malignancy (HHM, ~80%) : Tumor secretion of Parathyroid Hormone-related Protein (PTHrP) , which binds PTH-1 receptors in bone and kidney, stimulating osteoclast bone resorption and renal tubular calcium reabsorption. Associated with squamous carcinomas (lung, head/neck), renal cell, and breast cancer.
Local Osteolytic Hypercalcemia (~20%) : Direct osteolytic bone destruction by bone metastases mediated by local RANKL and cytokine release (breast cancer, multiple myeloma).
Ectopic 1,25-Dihydroxyvitamin D Production : Overproduction of active calcitriol by malignant lymphocytes in Hodgkin and non-Hodgkin lymphomas.
Ectopic Parathyroid Hormone (PTH) Secretion : Rare (<1%).
- 5. HCM Clinical Features & Diagnostic Assessment
- Clinical Presentation Matrix
Renal : Polyuria, polydipsia, nephrogenic diabetes insipidus, acute volume depletion, nephrolithiasis.
Gastrointestinal : Anorexia, nausea, severe constipation, obstipation, pancreatitis.
Neurological : Lethargy, confusion, hyporeflexia, muscle weakness, stupor, coma ("psychiatric overtones").
Cardiovascular : Shortened QTc interval, bradycardia, AV block, digitalis toxicity sensitivity.
Corrected Calcium Calculation
Serum calcium must always be adjusted for hypoalbuminemia: Corrected Calcium (mg/dL) = Measured Total Calcium (mg/dL) + 0.8 × [ 4.0 − Serum Albumin (g/dL) ] \text{Corrected Calcium (mg/dL)} = \text{Measured Total Calcium (mg/dL)} + 0.8 \times [4.0 - \text{Serum Albumin (g/dL)}] Corrected Calcium (mg/dL) = Measured Total Calcium (mg/dL) + 0.8 × [ 4.0 − Serum Albumin (g/dL) ]
Severity : Mild ( 10.5 – 11.9 mg/dL 10.5–11.9\text{ mg/dL} 10.5–11.9 mg/dL ), Moderate ( 12.0 – 13.9 mg/dL 12.0–13.9\text{ mg/dL} 12.0–13.9 mg/dL ), Severe ( ≥ 14.0 mg/dL \ge 14.0\text{ mg/dL} ≥ 14.0 mg/dL or symptomatic).
6. HCM Emergency Management Protocol
Agent / Intervention Mechanism of Action Onset & Duration Clinical Considerations
IV 0.9% Normal Saline Volume expansion; restores GFR and promotes renal calciuresis. Immediate Administer 200 – 500 mL/hr 200–500\text{ mL/hr} 200–500 mL/hr (2–4 L in first 24 hrs). Loop diuretics (furosemide) added ONLY after full rehydration.
Zoledronic Acid Intravenous bisphosphonate; inhibits osteoclast-mediated bone resorption. Onset 24–48 hrs; Peak 4–7 days Dose: 4 mg IV over ≥ 15 \ge 15 ≥ 15 min. Dose-adjust for renal impairment; monitor serum creatinine.
Denosumab (Xgeva) Monoclonal antibody targeting RANKL; inhibits osteoclast maturation/survival. Onset 2–4 days; Duration 1–2 months Dose: 120 mg SC (days 1, 8, 15, then monthly). Preferred in severe renal impairment ( CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min ).
Calcitonin Direct inhibition of osteoclastic resorption & renal calcium reabsorption. Onset 2–4 hrs; Duration 48 hrs Dose: 4–8 IU/kg SC/IM Q12H. Provides rapid short-term bridge; tachyphylaxis develops after 48 hrs.
Corticosteroids Inhibits calcitriol production & intestinal calcium absorption. Onset 2–5 days Prednisone 40–60 mg PO daily. Indicated for steroid-responsive malignancies (lymphoma, myeloma).